Key points are not available for this paper at this time.
Long-acting injectable formulations, if safe and well tolerated, may improve pharmacokinetic coverage of exposures to HIV infection. Complexities around safety, tolerability, and starting/stopping protocols require careful consideration.
Landovitz et al. (Wed,) studied this question.